Engineered immune cells take on stubborn leukemia in first safety test
NCT ID NCT06649227
First seen Jan 07, 2026 · Last updated May 01, 2026 · Updated 16 times
Summary
This early-phase study tests whether specially engineered immune cells (CD19 CAR-T cells) are safe for adults with relapsed or treatment-resistant acute myeloid leukemia (AML) that carries a CD19 marker. Only 5 participants will be enrolled. The goal is to monitor side effects and see if the treatment can control the disease, not to cure it.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED ADULT AML are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CHU de Lille
RECRUITINGLille, 59000, France
Contact
Conditions
Explore the condition pages connected to this study.